The ongoing GAIN Trial, a Phase 2/3 clinical trial of COR388 in Alzheimer’s disease, is fully enrolled and data is expected Q4 2021. COR388, was previously well tolerated in a Phase 1b trial in healthy subjects and patients with Alzheimer’s disease.
Clinical Trials
Current Studies
The GAIN Clinical Trial
The GAIN Trial (GingiPAIN inhibitor for treatment of Alzhimer’s disease) is a Phase 2/3 randomized, double-blind, placebo-controlled study that is assessing the efficacy, safety, and tolerability of two dose levels of COR388 oral capsules in subjects with mild to moderate Alzheimer’s disease. Randomized participants enter a screening period of up to six weeks, a 48-week treatment period, and a safety follow-up period of an additional six weeks.
The GAIN Trial has enrolled 643 participants in the United States, France, Spain, Poland, UK and Netherlands.
Visit www.GAINtrial.com for more information.